CPH News and Events

Opeyemi Olabisi is among the 2025 researchers elected to the American Society for Clinical Investigation (ASCI), one of the nation’s oldest medical honor societies.

Using Genetic Tools to Prevent Disease

Affiliate Duke CTSI faculty members Keisha Bentley-Edwards, PhD, and Senthil Selvaraj, MD, have been named to the 2025 Office for Faculty leadership programs at Duke University School of Medicine.

Early in her career as a breast surgical oncology fellow, Hwang questioned the standard practice of treating patients diagnosed with ductal carcinoma in situ (DCIS) — a small cluster of abnormal cells in breast ducts — with mastectomies or lumpectomies, often followed by radiation.

The first study comparing surgery to active monitoring as treatment for ductal carcinoma in situ (DCIS) finds women who carefully monitor the precancerous cells are no more likely to develop breast cancer after two years than women who undergo surgery to remove them.

The Center for Precision Health has welcomed Opeyemi Olabisi, MD, PhD, associate professor of medicine. Olabisi's research focuses on APOL1 variants that contribute to the progression of kidney disease. His ultimate goal is to translate his findings into improved diagnostic and treatment approaches for chronic kidney disease. As a clinician, Olabisi cares for individuals with various degrees of kidney disease. He is passionate about raising awareness about kidney disease and introduce remedies that could slow the progression of kidney disease.

Currently, many patients receive inconclusive results from genetic testing, leaving them without a clear diagnosis or a path forward for treatment, but a new model developed by researchers at Duke University could help increase the number of patients receiving positive test results, providing them with valuable information that could guide treatment decisions. Results were published in Circulation: Genomic and Precision Medicine.

The Duke Center for Precision Health and Precision Genomics Collaboratory have awarded five pilot grants to advance genomic science at Duke by leveraging and enhancing the OneDukeGen study infrastructure. This opportunity was open to all Duke University School of Medicine faculty.

With a career that started at NASA and ended with engineering software for genomics research, Duke patient Sharon is not shy about her passion for science and the value of scientific research. It should come as no surprise then that when, during an appointment at the Duke Cardiac Catheterization Lab, she was asked to join the OneDukeGen study, she was all in.

Driven by a deep desire to heal, Mihai V. Podgoreanu, MD, searches for solutions as he seeks to transform perioperative medicine and critical care into a system that is not just reactive, but predictive, preventive, and personalized.